anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Glaucoma is comprised of a group of optic neuropathies that share certain biological and clinical characteristics including progressive loss of the RGCs that causes specific, irreversible changes to the optic disc and visual field Visualization of the anterior chamber (AC) angle is a critical step in the diagnosis of glaucoma, especially angle-closure variants. .

UBM has been used in imaging and quantitative evaluation of anterior ocular segments since the 1990s. It allows in vivo observation of the anatomy and pathology of the anterior segments, from the conjunctiva and cornea to the iris and basal vitreous body, which provides significant information on glaucoma, cysts, neoplasms, trauma and foreign bodies. UBM also provides biometric information of anterior segment structures, such as anterior chamber (AC) depth, anterior chamber angle (ACA), and iris thickness. UBM provides more detailed information compared to slit-lamp, gonioscopy or B-scan examinations for diagnosis and follow-up of PAC eyes.In some cases UBM elucidates the mechanism of elevated intraocular pressure by showing the relationship between the peripheral iris and the trabecular meshwork. It can be used to study the causes of secondary glaucoma, for example, the pigment dispersion syndrome, lens-induced glaucoma, ciliary block, cysts, and solid tumors of the anterior segment. It can also assess the effects of various interventions such as laser iridotomy, trabeculectomy, and non-penetrating drainage surgery. Precise quantitative evaluation of the anterior chamber angle structures can help in diagnosis and management of various pathologies related to glaucoma . Optical coherence tomography (OCT) is a widely used non-invasive fundus imaging technique. Since the first application of OCT in the cornea in 2002\], anterior segment-optical coherence tomography (AS-OCT) has developed rapidly. There are two major OCT platforms on the market: time domain-optical coherence tomography (TD-OCT) and spectral (or Fourier) domain-optical coherence tomography (SD/FD-OCT) . With a higher imaging resolution than UBM, AS-OCT makes it easier for the operator and software to identify ACA structures. such as: the scleral spur (SS), iris surface, Schwalbe's line, even trabecular meshwork (TM), and Schlemm's canal. This provides more precise analysis of the angle opening distance (AOD) from the SS, ACA, trabecular iris angle (TIA), and trabecular iris space area (TISA)
BACKGROUND: This retrospective clinical study was undertaken to comparatively evaluate the number of restorative treatments, endodontic treatments, and tooth extractions performed for patients under general anesthesia due to dental anxiety or special needs between 2015 and 2022 and to examine the pain, bleeding, nausea, and vomiting data of those patients.
METHODS: In total, 1165 patients underwent dental treatment under general anesthesia in the faculty hospital. Those under the age of 15 and with no endodontic procedure planned (n = 918) were excluded, followed by those with incomplete data (n = 25) and those without endodontic treatment (n = 25). Patients who underwent at least one endodontic treatment were finally included in the study (n = 184). Patients were divided into two groups: healthy and with special needs. Dental treatments were recorded as endodontic, restorative, and teeth extractions. Endodontic treatments were classified according to the tooth type (premolar, molar, and incisors). The composite restorations were classified as anterior, occlusal (O), occluso-distal (OD) or occluso-mesial (OM), and mesio-occluso-distal (MOD) restorations and patients' post-treatment pain, nausea, vomiting, and bleeding were recorded. The data were analyzed statistically.
RESULTS: Among the 184 patients included in the study, 70 (38%) were healthy, and 114 (62%) had special needs. Postoperative bleeding was observed more in patients with special needs (χ2 = 4.189, p < 0.05), whereas pain was observed more in healthy patients (U = 2922.00, p < 0.05). While the number of anterior, O, and MOD restorations was higher in patients with special needs, the number of OD or OM restorations was higher in healthy patients (χ2 = 74.877, p < 0.05).
CONCLUSIONS: Patients with special needs undergo a greater number of restorative treatments compared to control patients, which may be associated with the inadequate oral hygiene care of such patients. However, restorative treatment is mostly indicated for such patients in our faculty hospital, which may indicate that a conservative approach is taken. Additionally, the finding that postoperative bleeding was more severe in this group of patients compared to the control group in this study may emphasize the need to consider more possible complications after general anesthesia in these patients.
The Boppli device will be applied to the patients' arm or foot on either side of the body and is intended for single use of up to 72 hours and is discarded following use. The device will only be used in patients requiring continuous blood pressure monitoring, through the use of an invasive arterial line (IAL), to compare the data obtained by the Boppli to that obtained by the IAL.
PROBLEM TO BE SOLVED: To improve a use effect and safety without degrading the taste and use feel of an object to be added with this deodorant by using the tannin extracted from Caesalpiniaceous spinosa as an effective component. SOLUTION: This deodorant is formed by using the tannin extracted from the legumes of the spinosa of the Leguminoous perennial plants grown in the dry zones in the Western parts of the South American continent as the effective component. The extracted tannin is the hydrolysis decomposition type gallotannin basically consisting of a structure in which plural pieces of gallic acids are ester bonded to a quinic acid which is cyclic polyhydric alcohol. This tannin is extracted by water, hydrophilic org. solvent or their mixture by pulverizing the trunks, branches, legumes and pericarps of the spinosa as they are or after drying the same. Methanol, ethanol, etc., are usable as the hydrophilic org. solvent. As a result, the deodorization of the object to be added with the deodorant is made possible without impairing the taste and use feel thereof.
Clinically, the Fear of Harm phenotype is characterized by early age of onset, severe mood swings, treatment resistance, separation anxiety, fearful-aggressive obsessions, parasomnias (e.g. night-terrors) and thermal dysregulation (Papolos et al. 2009). These youth typically received little benefit from standard treatments (i.e., antipsychotic medication and mood stabilizers) often wind up home-schooled due to excessive fears of the school environment and frequently require multiple periods of inpatient care (Papolos et al. 2009; Papolos et al. 2013). Key features seen in FOH that distinguish these youths from other youths with BD include fear sensitization and thermal dysregulation. Children with FOH often experience thermal discomfort (e.g., feeling hot, excessive sweating) in neutral ambient temperature conditions, as well as no discomfort during exposure to the cold, and alternate noticeably between being excessively hot in the evening and cold in the morning (Murphy, Frei, and Papolos 2014). Ketamine, an NMDA receptor antagonist was selected as a potential treatment for FOH because of its effectiveness in the reduction of fear sensitization and capacity to dose-dependently lower body temperature in animal studies, and has been found to be clinically efficacious in the treatment of FOH (Papolos et al. 2018; Papolos et al. 2013). There are two main reasons for proposing to conduct a neuroimaging study. First, intranasal ketamine can produce an almost immediate improvement in clinical state. This makes it possible to scan a subject whose dose of ketamine has largely worn off in order to assess blood flow and functional connectivity and then to rescan the individual within hours of receiving intranasal ketamine in order to correlate degree of clinical improvement with alterations in blood flow and connectivity. This will provide information on both the neurobiological basis of ketamine response and information on the possible biological underpinnings of FOH. Second, there is some concern, based on a report of examining brain scans in chronic ketamine abusers, that ketamine in daily doses 10X higher than clinically prescribed every 3-4 days can produce some evidence for structural brain damage4. Hence, it would be valuable to scan individuals undergoing long term treatment with intranasal ketamine to rule out or monitor for pathological changes in brain structure.
Type I diabetes, also known as insulin-dependent diabetes, is a chronic disease in which the pancreas produces insufficient insulin to properly regulate blood sugar levels. Hypoglycemia, or low blood sugar, and hyperglycemia, or high blood sugar, can lead to significant complications in people with type 1 diabetes. Intensive insulin therapy has been shown to reduce the risk of chronic complications in people who achieve near normalization of glycemia. However, this therapy is labor intensive, difficult to implement, and associated with an increased frequency of severe hypoglycemia. Transplantation of islets from a healthy pancreas has been successful in restoring normal blood sugar levels and has led to initial insulin independence in people with type 1 diabetes. Rejection of these islets by the recipient's immune system, however, can make the treatment ineffective. An immune response known as instant blood-mediated inflammatory reaction (IBMIR) results in the disruption of islet integrity and islet loss within an hour of transfusion. LMW-SD inhibits IBMIR by preventing the cascade that triggers it, when combined with pancreatic islets. The purpose of this study is to determine the safety and efficacy of LMW-SD given with islet transfusion and post-transfusion along with immunosuppressive therapy, including mycophenolate mofetil or sirolimus, tacrolimus or cyclosporine, and thymoglobulin or basiliximab, on the success of islet transplantation in people with type 1 diabetes.

This study will last for 1 year after the final islet transplant. Participants may receive up to 3 islet transplants while participating in this study. Participants eligible for this study will have clinic visits every 6 months. Once a preparation of islets becomes available, participants will be randomly assigned to Arm 1 or Arm 2. Participants in Arm 1 will receive LMW-DS during and for 5 hours after infusion. Participants in Arm 2 will receive heparin at the time of infusion. In addition, all participants will receive anticoagulation prophylaxis agents consisting of Klexzane® (Enoxaparinsodium) and Trombyl® or Albyl-E® (Acetylsalicylic acid). All participants will also receive the oral immunosuppression medications consisting of mycophenolate mofetil or sirolimus and tacrolimus or cyclosporine throughout the study. In addition, they will receive intravenous thymoglobulin on days -2, -1, day 0 (transplant), +1, and +2 for the first transplant or intravenous basiliximab at the time of transplant and on Day 4 for the second and third transplant. Enbrel® (Etanercept) will be given to all participants for anti-inflammatory therapy. Islet infusions will occur at the hospital and will be given intravenously. Participants will be eligible to receive second and third islet infusions if previous infusions fail and they continue to meet the eligibility criteria. After each infusion, study visits will occur on Days 1, 3, 7, 14, 21, 28, and 75 and Months 6 and 12. At these visits, physical exams and blood collection will occur. At some visits, urine collection will also occur.
Therapy with hydroxyurea requires close supervision. The complete status of the blood, including bone marrow examination, if indicated, as well as kidney function and liver function should be determined prior to, and repeatedly during, treatment. The determination of the hemoglobin level, total leukocyte counts, and platelet counts should be performed at least once a week throughout the course of hydroxyurea therapy. If the white blood cell count decreases to less than 2500/mm3, or the platelet count to less than 100,000/mm3, therapy should be interrupted until the values rise significantly toward normal levels. Severe anemia, if it occurs, should be managed without interrupting hydroxyurea therapy. 

Hydroxyurea should be used with caution in patients with marked renal dysfunction (see CLINICAL PHARMACOLOGY, Special Populations and DOSAGE AND ADMINISTRATION). 

Hydroxyurea is not indicated for the treatment of HIV infection; however, if HIV-infected patients are treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine, close monitoring for signs and symptoms of pancreatitis is recommended. Patients who develop signs and symptoms of pancreatitis should permanently discontinue therapy with hydroxyurea (see WARNINGS and ADVERSE REACTIONS). 

An increased risk of hepatotoxicity, which may be fatal, may occur in patients treated with hydroxyurea, and in particular, in combination with didanosine and stavudine. This combination should be avoided.
INTRODUCTION: This study aimed to explore the patterns of association between dual-tasking, cognition, ambulation disability, fatigue, and self-efficacy and their pathways in predicting social participation in persons with multiple sclerosis (MS).
METHODS: Adults with MS (n = 1162) completed an online survey. Social participation was assessed by the Quality of Life in Neurological Disorders. The Dual-task Impact on Daily-Living Activities Questionnaire, Multiple Sclerosis Walking Scale-12v2, and Modified Fatigue Impact Scale measured dual-tasking, ambulation, and fatigue, respectively. Fall Efficacy Scale-International and Self-Efficacy for Community Mobility were assessed and modeled as a latent variable for efficacy.
RESULTS: The correlation matrix showed significant associations of social participation with dual-tasking, cognition, ambulation, efficacy, and fatigue (all p < 0.001) and interrelationships among the independent variables (p < 0.05). The final model showed excellent global model fit (CFI = 0.99, TLI = 0.96), with all variables significantly predicting social participation either directly or indirectly. Efficacy significantly mediated the effects of dual-tasking (β=-0.32, p < 0.001) and ambulation disability (β=-0.42, p < 0.001) on social participation.
CONCLUSION: This study indicated that dual-tasking, ambulation disability, fatigue, and efficacy play important roles in social participation in persons with MS. The findings can help provide insight into factors that may underpin social participation and offer targets for interventions in persons with MS.
Standard of care anti-TB treatment. (10 mg/kg oral rifampicin, 5 mg/kg oral isoniazid, 15 mg/kg oral ethambutol and 25 mg/kg oral pyrazinamide daily for 2 months as fixed dose combination tablets (followed by 10 mg/kg oral rifampicin and 5 mg/kg isoniazid daily for 4-7 months in routine care after study completed)).
TAK-700 and standard androgen deprivation therapy (ADT) beginning two months prior to radiation therapy (RT). ADT comprised of anti-androgen continuing for two years and GnRH agonist stopping at end of RT. TAK-700 continues for two years.
1409533 Antiperspirant and deodorant compositions UNILEVER LTD 18 Jan 1973 [20 Jan 1972] 2840/72 Heading A5B Non-staining aerosol antiperspirant or deodorant compositions comprises an antiperspirant agent and/or germicide and 2-ethyl-1, 3- hexanediol as an emollient substance or dispersant, and a propellant. The germicide may be chlorhexidine, dichlorophene or cetyltrimethyl ammonium bromide. The antipespirant agent may be aluminium chlorhydrate or zinc phenolsulphonate. The compositions may also contain a surfactant, a bulking agent e.g. a silica, clay, talc and aluminium stearate, and/ or a perfume. The composition may be in the form of an aqueous alcoholic or aqueous/ alcoholic solution.
[GB1409533A]
The invention provides a feed for preventing swine high fever, which comprises houttuynia cordata. The feed has the following formula proportion: 64.5-62.5 percent of corn meal, 10 percent of bran, 20-25 percent of concentrated feed, 0.5 percent of salt and 2-5 percent of houttuynia cordata. In the specific using process of the feed, the preventive dose for each porket is in the range of 20 to 30 grams per time, the preventive dose for each moderate adult pig is in the range of 30 to 50 grams per time, the therapeutic dose for each porket is in the range of 50 to 100 grams per time and the therapeutic dose for each moderate adult pig is in the range of 100 to 150 grams per time. Due to the adoption of the large number of houttuynia cordata produced locally and low price of houttuynia cordata, the feed has the price advantage. Tests of preventing and treating the swine high fever by Chinese medicinal herbs and clinical application show that compared with antibiotics, the feed has obvious prevention and treatment effects. The feed is accepted by owners of scale pig farms. Due to the application of Chinese medicinal herbs in prevention and treatment of the swine high fever, the drug tolerance and the drug resistance are difficult to generate, no drug residues are generated, and the feed is environment-friendly.
INCA033989 will be administered at a protocol defined starting regimen in 28-day cycles to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with essential thrombocythemia (ET) will enroll in this group.
The SET binding protein 1 (SETBP1) gene encodes a transcription factor (TF) involved in various cellular processes. Variants in SETBP1 can result in three different diseases determined by the introduction (germline vs. somatic) and location of the variant. Germline variants cause the ultra-rare pediatric Schinzel Giedion Syndrome (SGS) and SETBP1 haploinsufficiency disorder (SETBP1-HD), characterized by severe multisystemic abnormalities with neurodegeneration or a less severe brain phenotype accompanied by hypotonia and strabismus, respectively. Somatic variants in SETBP1 are associated with hematological malignancies and cancer development in other tissues in adults. To better understand the tissue-specific mechanisms involving SETBP1, we analyzed publicly available RNA-sequencing (RNA-seq) data from the Genotype-Tissue Expression (GTEx) project. We found SETBP1 and its known target genes were widely expressed across 31 adult human tissues. K-means clustering identified three distinct expression patterns of SETBP1 targets across tissues. Functional enrichment analysis (FEA) of each cluster revealed gene sets related to transcriptional regulation, DNA binding, and mitochondrial function. TF activity analysis of SETBP1 and its target TFs revealed tissue-specific TF activity, underscoring the role of tissue context-driven regulation and suggesting its impact in SETBP1-associated disease. In addition to uncovering tissue-specific molecular signatures of SETBP1 expression and TF activity, we provide a Shiny web application to facilitate exploring TF activity across human tissues for 758 TFs. This study provides insight into the landscape of SETBP1 expression and TF activity across 31 non-diseased human tissues and reveals tissue-specific expression and activity of SETBP1 and its targets. In conjunction with the web application we constructed, our framework enables researchers to generate hypotheses related to the role tissue backgrounds play with respect to gene expression and TF activity in different disease contexts.
PURPOSE: A mushroom fermentation extract which is fermented by Lactobacillus and a composition containing the same are provided to suppress mouse-derived hepatoma without side effects. CONSTITUTION: A mushroom fermentation extract is obtained by fermenting mushroom using Lactobacillus bacteria. A method for preparing the mushroom fermentation extract comprises: a step of slicing mushroom(S110); a step of adding extract solvent(S120); a step of sterilizing in a sterilizer(S130); a step of inoculating the Lactobacillus bacteria and culturing(S140); and a step of filtering the culture and freeze-drying(S150). The extraction solvent is water, alcohol of C1-C4 or mixture thereof. A cosmetic composition or pharmaceutical composition containg the mushroom fermentation extract as an active ingredient. The pharmaceutical composition is anti-oxidant, antibacterial agent or anti-allergic agent.
Effects on Reproduction: 

Reproduction studies in rats fed chlordiazepoxide hydrochloride, 10, 20 and 80 mg/kg daily (2.4, 4.8 and 19.4 times, respectively, the maximum recommended clinical dose of 40 mg/day, and bred through one or two matings showed no congenital anomalies, nor were there adverse effects on growth of the newborn. However, in another study at 100 mg/kg daily there was noted a significant decrease in the fertilization rate and a marked decrease in the viability and body weight of offspring which may be attributable to sedative activity, thus resulting in lack of interest in mating and lessened maternal nursing and care of the young. One neonate in each of the first and second matings in the rat reproduction study at the 100 mg/kg dose (24.2 times the maximum recommended human dose of 40 mg/day, based on body surface area) exhibited major skeletal defects. 

Two series of reproduction experiments with clidinium bromide were carried out in rats, employing dosages of 2.5 and 10 mg/kg daily(1.2 and 4.9 times, respectively, the maximum recommended clinical dose of 20 mg/day, based on body surface area) in each experiment. In the first experiment, clidinium bromide was administered for a 9-week interval prior to mating; no untoward effect on fertilization or gestation was noted. The offspring were taken by caesarean section and did not show a significant incidence of congenital anomalies when compared to control animals. In the second experiment, adult animals were given clidinium bromide for 10 days prior to and through two mating cycles. No significant effects were observed on fertility, gestation, viability of offspring or lactation, as compared to control animals, nor was there a significant incidence of congenital anomalies in the offspring derived from these experiments. 

A reproduction study was carried out in rats through two successive matings with administration of oral daily doses of 2.5 mg/kg chlordiazepoxide hydrochloride and 1.25 mg/kg clidinium bromide(0.6 times the maximum recommended clinical dose for both drugs, based on body surface area) or 25 mg/kg chlordiazepoxide hydrochloride and 12.5 mg/kg clidinium bromide (6.1 times the maximum recommended clinical dose for both drugs, based on body surface area). In the first mating, no significant differences were noted between the control or the treated groups, with the exception of a slight decrease in the number of animals surviving during lactation among those receiving the high dosage. In the second mating, similar results were obtained except for a slight decrease in the number of pregnant females and in the percentage of offspring surviving until weaning. No congenital anomalies were observed in both matings in either the control or treated groups.